Table 3 Antimicrobials used for the patients with carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis bacteremia*
Main agents used | No. of patients | APACHE II score | No. (%) of patients | |
|---|---|---|---|---|
|  |  | Median (interquartile range) | Appropriate antimicrobial therapy | 14–day mortality |
Anti-pseudomonal penicillinsa | ||||
CRAB | 12 | 31.5(22.8–39.0) | 2(16.7) | 6(50.0) |
CRAN | 8 | 24(19.0–33.0) | 7(87.5) | 2(25.0) |
Anti-pseudomonal cephalosporinsb | ||||
CRAB | 14 | 26(22.8–34.0) | 2(14.3) | 4(28.6) |
CRAN | 10 | 26(19.3–30.0) | 7(70.0) | 1(10.0) |
Anti-pseudomonal fluoroquinolonesc | ||||
CRAB | 5 | 30(21.0–36.0) | 1(20.0) | 2(40.0) |
CRAN | 2 | 37.5(37.0–38.0) | 2(100.0) | 0(0) |
Anti-pseudomonal carbapenemsd | ||||
CRAB | 17 | 32(24.0–38.5) | 0(0) | 7(41.2) |
CRAN | 14 | 30.5(23.0–33.3) | 0(0) | 2(14.3) |
Ampicillin/sulbactam or sulbactam | ||||
CRAB | 11 | 17(15.0–33.0) | 4(36.4) | 5(45.5) |
CRAN | 8 | 24(18.0–27.5) | 3(37.5) | 0(0) |
Non-antipseudomonal β-lactamasese | ||||
CRAB | 6 | 17.5(15.3–25.3) | 0(0) | 1(16.7) |
CRAN | 9 | 18(15.5–24.0) | 3(33.3) | 1(11.1) |
Miscellaneous | ||||
CRAB | 6 | 25(17.8–32.0) | 0(0) | 2(33.3) |
CRAN | 13 | 27(16.0–35.5) | 0(0) | 3(23.1) |